407 related articles for article (PubMed ID: 25986747)
1. Tuberous Sclerosis: A New Frontier in Targeted Treatment of Autism.
Davis PE; Peters JM; Krueger DA; Sahin M
Neurotherapeutics; 2015 Jul; 12(3):572-83. PubMed ID: 25986747
[TBL] [Abstract][Full Text] [Related]
2. Genetic Etiologies, Diagnosis, and Treatment of Tuberous Sclerosis Complex.
Salussolia CL; Klonowska K; Kwiatkowski DJ; Sahin M
Annu Rev Genomics Hum Genet; 2019 Aug; 20():217-240. PubMed ID: 31018109
[TBL] [Abstract][Full Text] [Related]
3. Purkinje cells derived from TSC patients display hypoexcitability and synaptic deficits associated with reduced FMRP levels and reversed by rapamycin.
Sundberg M; Tochitsky I; Buchholz DE; Winden K; Kujala V; Kapur K; Cataltepe D; Turner D; Han MJ; Woolf CJ; Hatten ME; Sahin M
Mol Psychiatry; 2018 Nov; 23(11):2167-2183. PubMed ID: 29449635
[TBL] [Abstract][Full Text] [Related]
4. Restoration of Normal Cerebral Oxygen Consumption with Rapamycin Treatment in a Rat Model of Autism-Tuberous Sclerosis.
Chi OZ; Wu CC; Liu X; Rah KH; Jacinto E; Weiss HR
Neuromolecular Med; 2015 Sep; 17(3):305-13. PubMed ID: 26048361
[TBL] [Abstract][Full Text] [Related]
5. Brain Symptoms of Tuberous Sclerosis Complex: Pathogenesis and Treatment.
Mizuguchi M; Ohsawa M; Kashii H; Sato A
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34206526
[TBL] [Abstract][Full Text] [Related]
6. Vigabatrin inhibits seizures and mTOR pathway activation in a mouse model of tuberous sclerosis complex.
Zhang B; McDaniel SS; Rensing NR; Wong M
PLoS One; 2013; 8(2):e57445. PubMed ID: 23437388
[TBL] [Abstract][Full Text] [Related]
7. Rapamycin for treating Tuberous sclerosis and Autism spectrum disorders.
Ehninger D; Silva AJ
Trends Mol Med; 2011 Feb; 17(2):78-87. PubMed ID: 21115397
[TBL] [Abstract][Full Text] [Related]
8. Tuberous sclerosis: a review of the past, present, and future.
Uysal SP; Şahin M
Turk J Med Sci; 2020 Nov; 50(SI-2):1665-1676. PubMed ID: 32222129
[TBL] [Abstract][Full Text] [Related]
9. Tuberous sclerosis complex activity is required to control neuronal stress responses in an mTOR-dependent manner.
Di Nardo A; Kramvis I; Cho N; Sadowski A; Meikle L; Kwiatkowski DJ; Sahin M
J Neurosci; 2009 May; 29(18):5926-37. PubMed ID: 19420259
[TBL] [Abstract][Full Text] [Related]
10. mTOR Inhibitors in Children: Current Indications and Future Directions in Neurology.
Jeong A; Wong M
Curr Neurol Neurosci Rep; 2016 Dec; 16(12):102. PubMed ID: 27815691
[TBL] [Abstract][Full Text] [Related]
11. A circuitry and biochemical basis for tuberous sclerosis symptoms: from epilepsy to neurocognitive deficits.
Feliciano DM; Lin TV; Hartman NW; Bartley CM; Kubera C; Hsieh L; Lafourcade C; O'Keefe RA; Bordey A
Int J Dev Neurosci; 2013 Nov; 31(7):667-78. PubMed ID: 23485365
[TBL] [Abstract][Full Text] [Related]
12. [Neuropsychiatric manifestations in Tuberous Sclerosis Complex (TSC): diagnostic guidelines, TAND concept and therapy with mTOR inhibitors].
Waltereit R; Feucht M; de Vries MC; Huemer J; Roessner V; de Vries PJ
Z Kinder Jugendpsychiatr Psychother; 2019 Mar; 47(2):139-153. PubMed ID: 30080117
[TBL] [Abstract][Full Text] [Related]
13. Mechanism-based treatment in tuberous sclerosis complex.
Jülich K; Sahin M
Pediatr Neurol; 2014 Apr; 50(4):290-6. PubMed ID: 24486221
[TBL] [Abstract][Full Text] [Related]
14. Is tuberous sclerosis complex-associated autism a preventable and treatable disorder?
Curatolo P; Scheper M; Emberti Gialloreti L; Specchio N; Aronica E
World J Pediatr; 2024 Jan; 20(1):40-53. PubMed ID: 37878130
[TBL] [Abstract][Full Text] [Related]
15. Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of tuberous sclerosis complex.
Zeng LH; Rensing NR; Zhang B; Gutmann DH; Gambello MJ; Wong M
Hum Mol Genet; 2011 Feb; 20(3):445-54. PubMed ID: 21062901
[TBL] [Abstract][Full Text] [Related]
16. The role of mTOR inhibitors in preventing epileptogenesis in patients with TSC: Current evidence and future perspectives.
Schubert-Bast S; Rosenow F; Klein KM; Reif PS; Kieslich M; Strzelczyk A
Epilepsy Behav; 2019 Feb; 91():94-98. PubMed ID: 29941212
[TBL] [Abstract][Full Text] [Related]
17. Neuronal Tsc1/2 complex controls autophagy through AMPK-dependent regulation of ULK1.
Di Nardo A; Wertz MH; Kwiatkowski E; Tsai PT; Leech JD; Greene-Colozzi E; Goto J; Dilsiz P; Talos DM; Clish CB; Kwiatkowski DJ; Sahin M
Hum Mol Genet; 2014 Jul; 23(14):3865-74. PubMed ID: 24599401
[TBL] [Abstract][Full Text] [Related]
18. Mourning Dr. Alfred G. Knudson: the two-hit hypothesis, tumor suppressor genes, and the tuberous sclerosis complex.
Hino O; Kobayashi T
Cancer Sci; 2017 Jan; 108(1):5-11. PubMed ID: 27862655
[TBL] [Abstract][Full Text] [Related]
19. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
MacKeigan JP; Krueger DA
Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591
[TBL] [Abstract][Full Text] [Related]
20. [Autism, epilepsy and tuberous sclerosis complex: a functional model linked to mTOR pathway].
García-Peñas JJ; Carreras-Sááez I
Rev Neurol; 2013 Feb; 56 Suppl 1():S153-61. PubMed ID: 23446718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
